Truist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Jailendra Singh maintains a Hold rating on Hims & Hers Health (NYSE:HIMS) and raises the price target from $13 to $23.

July 18, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained a Hold rating on Hims & Hers Health and raised the price target from $13 to $23, indicating a positive outlook despite the Hold rating.
The increase in the price target from $13 to $23 suggests that the analyst sees significant upside potential for Hims & Hers Health. Although the Hold rating remains, the substantial increase in the price target is likely to be viewed positively by investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100